Science & Technology
Mriglobal
KANSAS CITY, MO
Total revenue
$118.0M
Total expenses
$115.3M
Net assets
$110.8M
Grants received
$2.9M
13 grants
EIN
440545878
Tax year
2023
Mission
Advance scientific and engineering research to support our government and commercial customers.
Programs
3 programs
Integrated Defense Solutions - MRIGlobal guards human health and safety by defending against chemical, biological, and explosive threats. With decades of chemical warfare agent detection, evaluation, and assessment, our unique expertise and history combines scientific and engineering experts with state-of-the-art laboratory facilities to advance programs across the United States government and private sectors. This includes the design, building, testing, and evaluation of advanced products and technologies such as miniature devices capable of detecting toxic materials and chemical agents, field-deployable laboratories, and medical response systems that improve national defense and global health.
Integrated Pharmaceutical Solutions - MRIGlobal bridges the gap between drug discovery and commercialization. We provide the necessary services including development, manufacturing, testing, and clinical trial material management support for drug substances, drug products, intermediates, and impurities, including reference standard materials. Our team works in the appropriate regulatory framework, such as GLP, GMP, and in accordance with ICH guidelines to ensure strict compliance to quality and regulatory requirements. This work helps support informed public health decisions, and guiding investigational new drugs through development, clinical trials, and regulatory approvals.
Translational Development - MRIGlobal scientists have unsurpassed technical expertise in defending against chemical and biological threats. This includes support for the discovery and development, and assessing the safety and efficacy, of regulatory compliant pre-clinical and non-clinical medical countermeasures to prevent or mitigate the adverse health effects of global health risks such as bioterrorism, infectious diseases, and chemical threat agents.
Financials
FY 2023
Revenue
Expenses
People
35 listed
Ian M Colrain PhD
President and CEO
$651K
40 hrs/wk
Martin J Nevshemal
CFO and Treasurer
$470K
40 hrs/wk
Amy M Bog PhD
Chief Innovation Officer
$333K
40 hrs/wk
Luke J McGlynn
Chief People Officer
$292K
40 hrs/wk
Jessica J Zolynas
Chief Legal Officer
$148K
40 hrs/wk
Pamela R Berneking
Director
$55K
1 hrs/wk
David B Dillon
Director
$48K
1 hrs/wk
David E Hall
Director
$48K
1 hrs/wk
Scott M Smith PE
Director
$48K
1 hrs/wk
William A Jeffrey
Director
$48K
1 hrs/wk
Amy Nachtigal
Director
$40K
1 hrs/wk
Neal Sharma
Director
$40K
1 hrs/wk
Wendy M Masiello
Director
$40K
1 hrs/wk
Stephanie B Easter
Director
$40K
1 hrs/wk
Dan E Arvizu PHD
Director
$40K
1 hrs/wk
Julia M Wilson
Director
$40K
1 hrs/wk
Douglas A Girod MD
Director
$40K
1 hrs/wk
David F Oliver
Director
$40K
1 hrs/wk
Reachel A Beichley
VP/General Counsel/Corp. Sec. - Outgoing
$645K
0Richard T Fleener
Sr VP-Lab Ops & Gov Affairs
$413K
40 hrs/wk
Richard A Winegar
Distinguished Research Fellow
$282K
40 hrs/wk
Dominie Garcia PhD
VP-Commercial Business Development
$258K
40 hrs/wk
Richard S Masino
Senior Sales Director
$258K
40 hrs/wk
Aaron M Heiss
Senior Sales Director
$257K
40 hrs/wk
Joseph A Bogan PhD
VP-Chief Research Fellow
$250K
40 hrs/wk
Gene G Olinger
Distinguished Research Fellow
$249K
40 hrs/wk
Kristine K Werking
Senior Director
$244K
40 hrs/wk
James E Sistrunk
Senior Sales Director
$233K
40 hrs/wk
Christopher W Hollars
Principal Advisor
$228K
40 hrs/wk
Dean E Gray
Chief Operating Officer - Outgoing
$222K
0Jerem G Swenddal
VP-Business Ops & Strategy
$213K
40 hrs/wk
Jonathan M White
Senior Director
$207K
40 hrs/wk
Carol F Blevins
Assistant Director
$193K
40 hrs/wk
Scott M King
VP-Business Operations - Outgoing
$189K
0Robert A Conklin
VP-Research Operations - Outgoing
$150K
0Independent contractors
Draper Laboratory
Research & Development
Domenix Corporation
Research & Development
Forgefx
Research & Development
Ohio State University
Research & Development
Conductive Technologies
Research & Development
Grants received
Showing 13 of 13
Funded by
$2.9M from 7 funders · 13 grants · 2017–2024
$2.3M · 6 grants · 2017–2023
$250K · 1 grant · 2020
$117K · 1 grant · 2020
$98K · 1 grant · 2020
$54K · 2 grants · 2022–2023
$50K · 1 grant · 2024
$25K · 1 grant · 2020